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Abstract
Human leukocyte antigen (HLA)-DRB3 is a functional HLA class II gene, which has a limited
allele diversity in the human population. Furthermore, the HLA-DRB3 gene is only present in
a subset of individuals. Therefore, in organ transplantation, this HLA molecule is frequently
mismatched between patient and graft donor and thus antibodies against this mismatched
HLA molecule can develop. In this study, we aimed to evaluate the prevalence and reactivity
of these antibodies and aimed to identify factors that underlie antibody formation against
HLA-DRB3. We showed in our patient cohort that HLA-DRB3 antibodies are identified in
about 7% of all patients that were screened with solid phase assays. In these assays, we
observed multiple antibody reactivity patterns indicating that HLA-DRB3 harbours multiple
epitopes. In those cases, where we succeeded at tracing back the induction of these anti-
bodies to the molecular HLA typing of the immunogenic event, we noticed a different fre-
quency of HLA-DRB1 allele groups in the donors as compared to a control group. To a
certain extent this distribution (e.g. HLA-DRB1*11 individuals) could be linked to an altered
expression level. However, it also appears that different HLA-DRB3 alleles (e.g. HLA-
DRB3*01 group) vary in their immunogenicity without having an expression difference. In
conclusion, our study provides information on the immunogenicity and reactivity patterns of
antibodies against HLA-DRB3 in kidney transplantation, and it points towards the possibility
of HLA expression as a factor underlying antibody formation.
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Introduction
Human leukocyte antigen (HLA) class II molecules, such as HLA-DR, play an important role
in the presentation of processed peptides from extracellular pathogens to the T cell receptor
(TCR) of CD4+ helper T cells [1, 2]. They are expressed on the surface of antigen presenting
cells (APC) like B cells, macrophages, and dendritic cells [3, 4]. The HLA-DR molecules are
heterodimers that consist of an alpha (α)-chain (encoded by HLA-DRA) that shows limited
diversity and a beta (β)-chain (encoded by e.g. HLA-DRB1) that is highly polymorphic in the
population [3, 5]. This high diversity influences the peptide presentation and as such deter-
mines an individuals’ ability to respond to a wide variety of pathogens. In addition, the allelic
variation in the population is thought to be a result of natural selection and represents a mech-
anism by which the population is protected against rapidly evolving pathogens [6].
The HLA-DRB1 gene was duplicated in evolution and subsequently some individuals
have a second HLA-DRB gene that encodes a functional protein on a single haplotype [7, 8].
These associated HLA-DRB proteins are tightly associated with HLA-DRB1 and are encoded
by HLA-DRB3, HLA-DRB4, and HLA-DRB5. Which of the associated HLA-DRB genes is
present on a single haplotype depends on which HLA-DRB1 allele is present, although excep-
tions are described. The HLA-DRB103, 11, 12, 13, 14 groups of alleles have a HLA-DRB3
gene, whereas the HLA-DRB104, 07, 09 groups of alleles have a HLA-DRB4 gene, the
HLA-DRB115, 16 alleles have a HLA-DRB5 gene, and the HLA-DRB101, 08, 10, groups
of alleles have no functional associated HLA-DRB gene [9, 10]. The associated HLA-DRB
gene products form together with the conserved α-chain (encoded by HLA-DRA), associated
HLA-DRB proteins. These associated HLA-DRB proteins are not present in all individuals,
but only in a subset (e.g. HLA-DRB3 is present in 43% of the caucasoid population). Further-
more, these associated HLA-DRB genes show allelic variation in the population, e.g. the
HLA-DRB3 gene shows modest allelic diversity with 145 alleles as compared to 2103 alleles of
HLA-DRB1 [10–14].
For HLA-DRB3 it has been shown that it contributes to antigen presentation and host
defence. In addition, the allelic variation of HLA-DRB3 has been proven to influence peptide
presentation. The most convincing evidence of this involves the presentation of the human
platelet antigen 1a (HPA-1a). The presentation of this HPA-1a peptide is highly restricted to
HLA-DRB301:01 [15]. Therefore, only carriers of this HLA-DRB3 allele are at risk to develop
HPA-1a antibodies, which can induce neonatal alloimmune thrombocytopenia (NAIT) and
fetal-maternal alloimmune thrombocytopenia (FMAIT) [16–19]. Besides NAIT and FMAIT
in which the presence of a specific HLA-DRB3 allele is a prerequisite for disease susceptibility,
HLA-DRB3 also contributes to the overall disease susceptibility for numerous autoimmune
diseases. These diseases include myasthenia gravis, Graves’ disease, Crohns’ sarcoidosis, and
primary sclerosing cholangitis [20–23].
In organ transplantation, it is well established that matching patients and donors with
respect to the HLA molecules has a major impact on the transplant survival [24]. The HLA
loci that have the most impact on transplant outcome are HLA-DRB1 followed by HLA-B
[25]. It is speculated that the importance of HLA-DRB1 and HLA-B is related to their higher
expression on the cell surface. There are studies that link the expression levels of different HLA
molecules to an altered capacity to induce an immune response against viral pathogens. For
example, the expression level of HLA-C affects the risk of graft versus host disease (GVHD)
after hematopoietic stem cell transplantation (HSCT), but also the clinical outcome of human
immunodeficiency virus infection and Crohn’s disease [26, 27]. Furthermore, high expression
of HLA-DPB1 and mismatches in HLA-DRB3 after HSCT was associated with the risk of
GVHD [28, 29].
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Since the number of HLA mismatches is correlated with inferior transplant outcome, it is
possible that the impact of HLA-DR matching is larger because HLA-DRB1 is associated with
the co-expressed HLA-DRB genes such as HLA-DRB3. Another factor contributing to the
survival of transplanted organs is the occurrence of rejection episodes. Even though major
improvements in the immunosuppressive strategies were made, rejection episodes are not pre-
ventive. At present, antibody mediated rejection (AMR) still plays a fundamental role in graft
loss in a subset of kidney recipients. In AMR, antibodies directed against mismatched HLA
molecules of the donor graft are associated with inferior transplant outcome [30–33]. Until
now, there is limited insight in the prevalence and importance of antibody formation against
HLA-DRB3 in solid organ transplantation (e.g. kidney). In addition, it remains unclear
whether factors such as expression levels of mismatched HLA molecules of the donor induce
antibody formation in transplant recipients.
In our study, we aimed to examine how frequent antibodies are observed against the
HLA-DRB3 protein in a kidney transplant cohort. We analysed the antibody reactivity pat-
terns and correlated the patterns to the immunizing event in order to establish whether cer-
tain HLA-DRB3 alleles are more immunogenic. Furthermore, we determined the gene and
protein expression of HLA-DRB3 and evaluated the graft outcome in recipients that develop
HLA-DRB3 antibodies after transplantation.
Materials and methods
Sera from patients and ethics
We made use of routine antibody screening of patients who undergo or await organ transplan-
tation in the Dutch transplant centers of Maastricht and Groningen. The collection, storage,
and usage of tissue and patient data have been performed in agreement with FEDERA (Federa-
tion of Dutch University Medical Centers) Code of Conduct (federa.org); According to Dutch
law, Institutional Review Board (IRB) approval was not required for scientific analysis of anon-
ymous data. Additionally, the research described in this article is according to Dutch standards
called ‘niet WMO plichtigheid’: medical scientific research that does not involve patients’
actions or behaviours. All patients who visited both hospitals are informed about the proce-
dure that material can be used for scientific research without further consent if the research is
according to this standard. Plus, the sera used in this study are defined as left-over from clinical
purposes and further use for medical research purposes is in accordance to Dutch ethical regu-
lations. Maastricht: A total of 1800 kidney patients were transplanted in the period 1982 to
2014. In 645 of these patients, sera were tested for the presence of HLA class II antibodies
using solid phase assays. Groningen: We applied a comprehensive database search for patients
(organ waiting list and after transplantation) in whom HLA-DRB3 specific antibodies were
demonstrated.
Control groups
To study which HLA-DRB3 allele is the most immunogenic, we determined the HLA-DRB3
high resolution typing of the immunizing events vs. a control group. Selection process of the
control group: A total of 140 HLA-DRB3 positive patients without HLA-DRB3 antibodies were
anonymously and randomly selected using our Maastricht transplant center database.
To examine whether certain donors are more prone to induce an HLA-DRB3 antibody
response, we determined the HLA-DRB3-linked HLA-DRB1 distribution (HLA-DRB103, 11,
12, 13, and 14) in the donor group vs. a control group. Selection process of the control
group: A total of 258 HLA-DRB3 positive patients (without HLA-DRB3 antibodies) with an
available HLA-DRB1 typing were anonymously and randomly selected using our Maastricht
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transplant center database. Both control groups were separately selected, so there is no overlap
in between these groups.
Detection of HLA-DRB3 antibodies using the Luminex Single Antigen
(LSA) assay
The HLA-DRB3 antibodies in the serum of patients were detected using the LABScreen SA
HLA class II assay (One Lambda, Thermo Fisher, Canoga Park, CA, USA) and Lifecodes LSA
class II assay (Immucor, Norcross, GA, USA) according to the manufacturers’ protocol. The
LABScreen (Lot: 009) and Lifecodes (Lot: 01145C) LSA kits contained three microbeads
coated with single HLA-DRB3 alleles that represent the three major allele groups of the
HLA-DRB3 protein: HLA-DRB301:01, HLA-DRB302:02, and HLA-DRB303:01. In short,
the microbeads coated with purified HLA class II molecules were incubated with patient
serum for 30min. Subsequently, antibodies that bound to HLA-DRB3 proteins coated on the
microbeads were detected with PE (phyco-erythrine)-conjugated goat anti-human IgG after
an incubation of 30min at room temperature. After washing, all microbeads were measured
with the Luminex 100 multiplex analyser (Luminex, Austin, TX, USA) and analysed using
HLA Fusion v.3.4 (One Lambda) and MatchIT v.1.2 (Immucor) software. In S1a Fig, an illus-
tration displays the LSA assay and the position of the HLA-DRB3 microbeads of both vendors.
The microbeads with a MFI value1000 were considered positive for HLA-DRB3.
CDC assay to determine the panel reactive antibody
1 μL serum of the patient was incubated with a screening panel of 60 different lymphocyte-sus-
pensions (1 μL suspension; 4 106 cells/mL) for 30min (RT). Subsequently, 5 μL rabbit comple-
ment (Life Technologies) was added and incubated for 60min (RT) to initiate lymphocyte lysis
via CDC. The addition of 5 μL FluoroQuench (One Lambda) for 10min (RT) allowed discrimi-
nation of intact versus lysed cells by means of automated fluorescence microscopy (Leica). In
this way, the panel-reactive antibody (PRA) can be determined. In case we were not able to
determine the PRA, we calculated the virtual PRA (vPRA) using the Eurotransplant reference
laboratory vPRA calculator. This tool calculates the vPRA based on unacceptable antigens for
HLA-A, -B, -C, -DR, and -DQ. The vPRA database contains data of 6870 donors with a com-
plete HLA typing.
Sequence based typing (SBT) of the HLA-DRB3 gene
The sequence based typing of HLA-DRB3 was previously described [34]. In short, the amplifi-
cation reactions of HLA-DRB3 were performed in a total mix volume of 30 μL that included 67
mM Tris-HCl (pH 8.8) (Merck, Darmstadt, Germany), 5% glycerol (Alfa Aesar, Karlsruhe,
Germany), 1.5 mM MgCl2 (Life Technologies), 0.01% Tween 20 (Merck), 16.6 mM ammo-
nium sulphate (Merck), 0.2 mM of each dNTP (GE Healthcare, Diegem, Belgium), 15 pmol
of each primer (Sigma-Aldrich, Zwijndrecht, The Netherlands), 0.1 μg/μL cresol red (Sigma-
Aldrich), 300 ng DNA, and 1.4 U expand high fidelity enzyme mix (Roche, Basel, Switzerland).
The cycling conditions consisted of 2min at 94˚C; 10 cycles of 15s at 94˚C, 30s at 63˚C, 4min
at 68˚C; followed by 10 cycles of 15s at 94˚C, 30s at 60˚C, 6min at 68˚C; followed by 10 cycles
of 15s at 94˚C, 30s at 60˚C, 10min at 68˚C, and 7min at 68˚C. The amplified products were
visualized and checked for size on a 1.5% agarose gel (Life Technologies) with a concentration
of 0.5 μg/mL ethidium bromide (Sigma-Aldrich).
The amplified products were sequenced using 4 sequence primers that covered exon 2 and
exon 3 of HLA-DRB3. The total sequence volume of 10 μL included 6 μL water, 0.5 μL primer
(5 pmol), 1 μL BigDye Terminator v1.1 mix, 1.5 μL BigDye Terminator sequencing buffer
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(Life Technologies), and 1 μL purified amplification product. The cycling conditions consisted
of 1min at 96˚C; 25 cycles of 10s at 96˚C; 5s at 50˚C, and 4min at 60˚C. After sequencing, the
products were purified with Sephadex G-50 (GE) and electrophoresed on the ABI 3730 DNA
analyzer (Applied Biosystems, Foster City, CA, USA). The sequence data were analysed using
Seqpilot v.3.5.2 software (JSI, Kippenheim, Germany).
B cell isolation for HLA-DRB1 and HLA-DRB3 quantitative PCR
During routine diagnostics, splenocytes from deceased donors were isolated for crossmatch
and typing purposes. The ethical regulations are described in the section ‘Sera from patients
and ethics’. The anonymous human material used in this study are defined as left-over and
the use of this material for research purposes is in accordance to Dutch ethical regulations.
In short, splenic parts from deceased donors were homogenized into a single cell suspension
using a gentleMACS dissociator (Miltenyi Biotec, Leiden, The Netherlands) (S1 Table). The
mononuclear cells were separated from the single cell suspension using Lymphoprep. The
obtained cells were frozen in RPMI-1640 medium containing 10% DMSO, 10% FCS and 1%
PenStrep and stored in liquid nitrogen. Upon thawing, 10 106 splenocytes were washed and
resuspended. Subsequently, B cells were isolated using the CD19 positive B cell isolation kit
per manufacturers’ protocol (Miltenyi Biotec). The obtained B cells were stained for purity
after the isolation using CD19 (clone HIB19, BD, APC), CD3 (clone UCHT1, BD, Horizon
V450), CD56 (clone B159, BD, PE-Cy7) and CD14 (clone M5E2, BD, FITC) and measured
using flow cytometry (BD FACS Canto II). The purity of the B cells exceeded99% (S3 Fig;
n = 5).
Quantitative PCR to determine the relative mRNA expression of
HLA-DRB1 and HLA-DRB3
Total RNA was isolated from lysed B cells (positive B cell isolation kit) using the RNeasy Mini
kit according to manufacturers’ protocol (Qiagen). Residual genomic DNA was removed by
DNase I treatment followed by reverse transcription using random hexonucleotide primers
and Superscript III Reverse Transcriptase according to a standard protocol (Invitrogen). The
forward and reverse primers for quantitative PCR are shown in S2 Table. To prevent DNA
amplification, both the HLA-DRB1 and HLA-DRB3 primers were designed to span exon-exon
boundaries with a maximal amplification length of 300bp. A standard curve of a reference
sample (cDNA of a total B cell fraction) was generated for relative quantification. The real-
time (RT)PCR was performed with SYBR green detection (SensiMix SYBR, Bioline Reagents,
London, UK) using the iCycler iQ (Biorad Laboratories, Hercules, CA, USA) and 10 pmol of
the specific primer. The PCR program consisted of 10min initial heating at 95˚C, followed by
35 cycles of amplification (30s at 95˚C, 20s at 62˚C, 20s at 72˚C) and a heating up to 92˚C to
create a melting curve (increased 0.5˚C/7s). The data represent the expression of the gene of
interest normalized to HuPo (human acidic ribosomal protein) or GAPDH [35], which were
used as reference genes in our study (S2 Table).
Assessment of the cell surface expression of HLA-DRB3 using flow
cytometry
Splenocytes from deceased donors were used to determine the cell surface expression of the
HLA-DRB3 protein (S1 Table). Spleens were homogenised to a single cell suspension, sepa-
rated with Lymphoprep, and the cells were stored in liquid nitrogen. At the moment of flow
cytometric assessment, 10 106 splenocytes were thawed, washed, resuspended, and counted.
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The flow cytometric procedure is shown in S5 Fig. In short, a total of 1 105 splenocytes were
blocked with heat-inactivated fetal calf serum (FCS) (20min, RT). Subsequently, mouse mono-
clonal antibody 7.3.19.1 specific for epitope 77N (Thermo Fischer) that is only present on
HLA-DRB3 (with the exception of HLA-DRB103) proteins was incubated for 30min. As con-
trol condition the IgG2b isotype control was added (clone 27–35, BD) to check for non-specific
binding. The B cell fraction was further specified with CD19 (clone HIB19, BD, APC). The
monoclonal 7.3.19.1 antibody was detected with a PE labelled goat anti-mouse Ig antibody
(20min, polyclonal, BD). In between all incubation steps the cells were washed with buffer
(PBS 1X, 1% FCS, 0.02% NaN3). Prior to staining of mouse anti-human CD19, mouse serum
(20min, Dako) was added to block the binding sites of the goat anti-mouse Ig antibody. A life
to death marker 7-AAD was added before measurement (BD). The cells were measured and
analysed using BD FACSCanto II and FACSDiva software. To standardize for the fluorescence
intensity irrespective of the instrument and software, PE labelled beads were used (Bangs Lab-
oratories Inc., Fishers, IN, USA). The mean fluorescent intensities (MFI) were adjusted to mol-
ecules of equivalent soluble fluorochromes (MESF) units [36].
Figures and statistics
The statistical analyses were performed in GraphPad Prism Pro v.6.01 (GraphPad Software,
La Jolla, CA, USA). The figures were made in Graphpad and combined in Adobe Illustrator
(Adobe Systems, San Jose, CA, USA). The difference in allele frequencies of HLA-DRB1 was
determined using the Chi-squared test. The Mann-Whitney t-test was used to define a statisti-
cal significance between groups. The Kaplan-Meier survival curves were compared using the
log-rank (Mantel-Cox) test. For all analyses, a P value <0.05 () was statistically significant.
P-values <0.01 were graphically presented as ().
Results
The prevalence and Luminex Single Antigen reactivity patterns of
HLA-DRB3 antibodies in the sera of organ transplant recipients
To study the prevalence of antibodies against HLA-DRB3, we made use of routine antibody
screening of patients that undergo or await kidney transplantation in the transplant centers
of Maastricht and Groningen. In Maastricht, 1800 kidney patients were included and in 645
of these patients, sera were tested in solid phase assays (LSA: Luminex Single Antigen) in
addition to cytotoxicity testing. A retrospective LSA analysis of these 645 patients showed
that 43 kidney patients (7%) were positive for HLA-DRB3 antibodies. In addition, in the
center of Groningen we applied a search in the local transplant database for patients in which
HLA-DRB3 were detected in routine antibody screening. Using this approach, we identified
42 additional patients with HLA-DRB3 antibodies. Notably, 6 out of these 42 patients were
waiting for their first lung or heart transplantation. Since transplantation was not the immuno-
genic event inducing HLA-DRB3 antibody formation, we consider these 6 patients as patients
on the waiting list for organ transplantation in whom pregnancy and/or transfusion is the
event that triggered HLA-DRB3 antibody formation. All cases where we identified organ
transplantation as immunogenic event were kidney transplant recipients. As shown in Fig 1,
we characterized a total of 85 positive patients based on their immunizing event (transplanta-
tion, transfusion, and/or pregnancy) and whether patients were carrying the HLA-DRB3 gene
or not.
Presence of allele-specific HLA class II antibodies in the sera of kidney patients was
assessed by use of LSA microbead assays (Maastricht from One Lambda and Groningen from
Antibodies against the HLA-DRB3 protein in kidney transplantation
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Immucor). As shown in S1a Fig, the LSA kits from One Lambda and Immucor contained
three microbeads coated with HLA-DRB301:01, HLA-DRB302:02, and HLA-DRB303:01
proteins. Although these LSA assays are similar in terms of methodology, both centers use
a different LSA vendor. Therefore, the LSA kits may have different antibody reactivity as a
result of the purification and coating of HLA-DRB3 proteins on the microbeads. We tested to
what extent the LSA kits from both vendors were consistent in terms of antibody reactivity
patterns. The data of this technical validation are presented in the supporting information
(S1 File and S1b Fig). The conclusion of this technical validation was that both kits are repro-
ducible in terms of determining whether a serum contains antibodies against HLA-DRB3 or
not. Though, both kits displayed discrepancies when detecting antibodies against specific
HLA-DRB3 alleles, especially against HLA-DRB303:01. We observed this in the sera of
HLA-DRB3 carriers.
As shown in Fig 2, examination of the LSA reactivity patterns for 85 positive patients
showed all seven HLA-DRB3 antibody reactivity patterns (group I to VII), confirming that
the HLA-DRB3 protein has multiple epitopes. Most of the patients (52 out of 85) displayed an
antibody reactivity to all three HLA-DRB3 microbeads (group VII) (mean fluorescent inten-
sity (MFI) value ±8500). Furthermore, 67 out of 85 patients who showed antibodies against
HLA-DRB3 are individuals who do not carry the HLA-DRB3 gene, while 18 patients were
HLA-DRB3 gene carriers. In terms of antibody reactivity patterns, these two groups act
Fig 1. Characterization of 85 positive patients with HLA-DRB3 antibodies based on their immunizing event and
whether patients and donors (children in case of pregnancy) were HLA-DRB3 gene carrier or not. We made use of
routine antibody screening of patients that undergo or await organ transplantation in the Dutch transplant centers of
Maastricht and Groningen. We detected in a total of 85 patients (n = 28 male and n = 57 female; black symbol)
HLA-DRB3 antibodies after different immunizing events such as kidney transplantation (tx; dark grey), transfusion (tf;
light grey), or pregnancy (p; medium grey). We also determined whether the patients and donors (children in case of
pregnancy) were HLA-DRB3 gene carrier or not. Mismatched cases are shown as—for patient DRB3 and + for donor
HLA-DRB3; and matched cases are shown as + for patient DRB3 and + for donor HLA-DRB3.
https://doi.org/10.1371/journal.pone.0203381.g001
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different: the sera of patients who do not carry the HLA-DRB3 gene (52 out of 67) showed an
antibody reactivity primarily against all three microbeads (S2a Fig) (group VII), while the sera
of patients who carry the HLA-DRB3 gene showed reactivity with specific DRB3 allele groups
(S2b Fig).
Immunization with HLA-DRB301 and HLA-DRB302 displayed more
induction of HLA-DRB3 antibodies in kidney patients as compared to
HLA-DRB303
To examine which HLA-DRB3 allele is the most immunogenic in terms of antibody induction,
we determined the HLA-DRB3 typing of the immunizing events (graft donor or child in case
of pregnancy). We did an HLA typing of the graft donors or children for HLA-DRB301,
HLA-DRB302, and HLA-DRB303 using SBT (exon 2 and 3). In 52 out of 85 patients we suc-
ceeded to identify the immunizing event and was it possible to obtain DNA for molecular typ-
ing of HLA-DRB3, while we had no DNA of the other 33 patients. In 28 cases the immunizing
event was a transplantation (graft donor), and in 24 cases a pregnancy. In Fig 3a, we showed
that 54% of the microbead reactivity patterns in the patients had an immunizing event with
HLA-DRB301, whereas 33% had HLA-DRB302, and 13% had HLA-DRB303. The distribu-
tion of HLA-DRB301 and HLA-DRB302 was significantly different compared to the control
group with 140 HLA-DRB3 positive individuals without HLA-DRB3 antibodies. In this control
group, we observed that 28% had HLA-DRB301, 55% had HLA-DRB302, and 17% had
HLA-DRB303. In Fig 3b, the correlation between the microbead reactivity pattern and the
nature of the immunizing event is shown. We did not notice reactivity patterns that did not
include the microbead coated with the sensitizing HLA-DRB3 molecule. The reactivity pattern
that recognized all three microbeads was observed most frequent (35 out of 52). Furthermore,
Fig 2. The reactivity patterns of HLA-DRB3 antibodies against Luminex SA microbeads. The reactivity patterns of
HLA-DRB3 antibodies against three LSA microbeads (One Lambda and Immucor) in 85 patients. The groups
represent all possible binding combinations of HLA-DRB3 antibodies in the sera of patients to one, two, or three
microbeads coated with HLA-DRB301:01, HLA-DRB302:02, and HLA-DRB303:01 proteins. A MFI value of1000
was considered to be positive for HLA-DRB3. The data is plotted as mean and SEM.
https://doi.org/10.1371/journal.pone.0203381.g002
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we observed that all possible reactivity patterns containing the microbead coated with the
HLA-DRB3 allele of the sensitizing event were observed.
Taken together, our data suggest that in kidney patients with HLA-DRB3 antibodies,
HLA-DRB301 was more immunogenic than HLA-DRB302 and HLA-DRB303. In addition,
the correlation of the donor typing with the microbead reactivity pattern showed that allele
group specific reactivity is a consequence of immunization and not an artefact of solid phase
assays. Therefore, also the allelic diversity of HLA-DRB3 is immunogenic.
The frequencies (measured by the HLA-DRB1 alleles that are associated
with HLA-DRB3) are different in the donor group as compared to a control
group
To address the hypothesis whether certain donors present peptides differently and are more
prone to induce an HLA-DRB3 antibody response, we investigated the HLA-DRB1 distribu-
tion in the donor group and a control group. The expression of HLA molecules can be depen-
dent on the haplotype organization. In case of broad antigens HLA-DRB3, HLA-DRB4, and
Fig 3. The immunologic events of HLA-DRB301, 02, 03 and the allele frequencies of HLA-DRB1 in the donors.
a, b. The immunologic events defined as the HLA-DRB3 (01, 02, 03) typing of the graft donors or children
(pregnancies) and the reactivity patterns of HLA-DRB3 antibodies against LSA microbeads HLA-DRB301:01, 02:02,
and 03:01 that were detected in HLA-DRB3 negative and positive kidney patients (n = 52). The percentages of the
patients’ LSA reactivity pattern that correspond with the HLA-DRB3 donor typing are shown in the pie chart. The
distribution of the HLA-DRB3 alleles of the graft donors or children are compared with a control group (HLA-DRB3
positive individuals without HLA-DRB3 antibodies). c. In 85 kidney patients HLA-DRB3 antibodies were detected.
With respect to the donor group, 59 graft donors or children were typed for HLA-DRB1. These HLA-DRB1 alleles
(linked to HLA-DRB3) were compared with a control group in a case-control setting. d. The allele frequencies of
HLA-DRB103, 11, 12, 13, and 14 are displayed as percentage. The difference between donor and control groups
was calculated using the Chi-squared test. The P values of<0.05 () and<0.01 () were statistically significant.
https://doi.org/10.1371/journal.pone.0203381.g003
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HLA-DRB5 the expression levels can be studied by analysing the linked HLA-DRB1 gene. We
assessed whether the allele frequencies of the HLA-DRB1 alleles (HLA-DRB103, 11, 12, 13,
and 14) that are linked with HLA-DRB3 of the immunizing event (donors or children in case
of pregnancy) showed a discrepancy in distribution as compared to control individuals. To
this end, we compared the distribution of HLA-DRB103, 11, 12, 13, and 14 alleles in the
immunizing event group to a total of 258 kidney transplant recipients carrying the HLA-DRB3
gene without the presence of HLA-DRB3 antibodies (control). As illustrated in Fig 3c, in 59
out of the 85 patients who had HLA-DRB3 antibodies we had DNA to perform HLA-DRB1
typing. As shown in Fig 3d, we observed a reduced allele frequency of HLA-DRB111 and
HLA-DRB112 in the donor group as compared to the control group. In addition, the allele
frequencies of HLA-DRB103, HLA-DRB113, and HLA-DRB114 were similar in the donor
group as compared to the control group. The altered distribution of the HLA-DRB1 alleles may
indicate that certain HLA-DRB1 alleles are more or less prone to induce antibodies in patients
with HLA-DRB3 antibodies.
The relative mRNA and protein expression of HLA-DRB1 and HLA-DRB3
To determine whether expression variances contribute to antibody induction, we assessed the
relative mRNA and protein expression of HLA-DRB1 and HLA-DRB3. The relative mRNA
expression of the HLA-DRB1 and HLA-DRB3 genes was determined with quantitative PCR.
We developed specific forward primers for HLA-DRB1 alleles HLA-DRB103, HLA-DRB111,
HLA-DRB113, and HLA-DRB114 and for HLA-DRB3 (S2 Table). HLA-DRB101 (no second-
ary HLA-DRB gene) was used as negative control for both primers (illustration Fig 4c). The
HLA-DRB1 primer did not allow amplification of HLA-DRB112. Since the allele frequency of
HLA-DRB112 is very low in the caucasoid population, we did not develop separate primers.
The relative mRNA expression of HLA-DRB103, 11, 13, and 14 and HLA-DRB3 was
assessed in B cells, and the values were normalized to the reference gene HuPo.
As shown in Fig 4a, B cells from individuals with HLA-DRB301 displayed a higher relative
mRNA expression than HLA-DRB302 (P<0.001) and HLA-DRB303 (P<0.01). Notably, in 4
individuals with HLA-DRB301 we observed a higher relative mRNA expression than the
other individuals. There was no difference between HLA-DRB302 and HLA-DRB303. With
regard to HLA-DRB1, we observed that the relative mRNA expression of all HLA-DRB1 alleles
(HLA-DRB103, 11, 13, 14) was higher as compared to HLA-DRB3 (Fig 4c). The expression
difference of HLA-DRB1 and HLA-DRB3 had an average of 5.3 ±1.9 fold. However, we did not
notice a substantial difference in relative mRNA expression among the different HLA-DRB1
alleles (HLA-DRB103, 11, 13, 14) and their linked HLA-DRB3. Comparable results were
observed when using GAPDH as reference gene (5.3 ±1.9 fold data; S4 Fig).
Subsequently, we determined whether the HLA-DRB3 protein expression is different
across these HLA-DRB1 alleles. We measured the HLA-DRB3 expression (monoclonal 7.3.19.1
antibody) on the cell surface of B cells using flow cytometry (S5a Fig). We preferred to use a
monoclonal antibody, since HLA molecules are highly polymorphic and due to this feature
polyclonal antibodies or sera may show increased cross-reactivity with other HLA molecules.
This makes it difficult to assess the cell surface expression of a specific HLA molecule. The B
cells were selected with CD19 positivity (S5b Fig). We included 5 donors with HLA-DRB103
as positive control, since the monoclonal antibody will bind to HLA-DRB1 and HLA-DRB3.
In addition, we selected 5 donors with HLA-DRB101 as negative control, since the monoclo-
nal antibody will not bind to HLA-DRB101, and HLA-DRB3 is absent (HLA-DRB101 is
not linked to HLA-DRB3). This approach allows us to compare the HLA-DRB3 expression in
donors with HLA-DRB111, 12, 13, and 14.
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Fig 4. The relative mRNA and protein expression of HLA-DRB1 and HLA-DRB3. a. The relative mRNA expression
of HLA-DRB301 (n = 9), 02 (n = 16), and 03 (n = 11) in isolated B cells from deceased donors. The relative mRNA
expression was determined by quantitative PCR (Q-PCR) and the values were normalized to reference gene HuPo. b.
The cell surface expression of HLA-DRB301 (n = 7), 02 (n = 15), and 03 (n = 9) on B cells. Splenocytes from the
donors were incubated with monoclonal 7.3.19.1 antibody, which binds to the specific epitope 77N that is present on
Antibodies against the HLA-DRB3 protein in kidney transplantation
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As shown in Fig 4b, there was no difference in cell surface expression of HLA-DRB3 alleles
HLA-DRB301, HLA-DRB302, and HLA-DRB303. This indicates that the increased relative
mRNA expression of HLA-DRB301 did not result in elevated cell surface expression. With
respect to the HLA-DRB1 alleles, we observed a reduced expression of the HLA-DRB3 protein
in 5 donors with HLA-DRB111 as compared to HLA-DRB112, and HLA-DRB113, but not
to HLA-DRB114 (Fig 4d). In case of HLA-DRB114, the expression of the HLA-DRB3 protein
is lower as compared to HLA-DRB112, but not to HLA-DRB111 and HLA-DRB113. In
addition, we showed that the monoclonal 7.3.19.1 antibody reacted with HLA-DRB1 and
HLA-DRB3 in 5 donors with HLA-DRB103 and that 5 donors with HLA-DRB101 showed no
antibody reactivity. The antibody reactivity is illustrated in Fig 4e.
Taken together, HLA-DRB301 showed a higher relative mRNA expression than
HLA-DRB302 and HLA-DRB303. Though, there was no difference in protein expression
among the HLA-DRB3 alleles. Likewise, we did not observe substantial differences in relative
mRNA expression of HLA-DRB3 between the linked HLA-DRB1 alleles. Nevertheless, we
observed a reduced protein expression of HLA-DRB3 in case of HLA-DRB111 and 14.
The graft survival in transplant recipients with or without HLA-DRB3
antibodies
In order to assess whether HLA-DRB3 antibodies develop in a specific subgroup of patients,
we retrospectively determined graft outcome in patients (n = 20) who displayed antibodies
after kidney transplantation. In 17 out of 20 patients the HLA-DRB3 antibodies developed
after transplantation. As shown in Fig 5a, 10 patients that developed HLA-DRB3 antibodies
demonstrated a transplant failure (return to dialysis) within 20 days after transplantation.
Notably, patients who showed these antibodies after transplantation displayed at the same
time antibodies against many other HLA molecules, which is indicated by a panel-reactive
antibody (PRA) of 74 ±21% (Fig 5b). The determination of the PRA using CDC assays is clini-
cally relevant as it indicates the presence of complement-fixing antibodies against 74% of the
Caucasoid donor population. Importantly, as shown in Fig 5c, in 15 out of 20 patients the
HLA-DRB3 antibody was detected after graft failure and transplantectomy. In 3 patients we
observed preformed HLA-DRB3 antibodies prior to transplantation and in 2 patients we
observed these antibodies prior to graft loss but not prior to transplantation. Furthermore, in
15 out of 20 patients with HLA-DRB3 antibodies data was available of the donor origin of the
transplanted grafts. All grafts were derived from post-mortem donors further defined as 5
grafts from donation after brain death (DBD) and 10 grafts from donation after cardiac death
(DCD) donors.
Discussion
HLA-DRB3 belongs to the HLA class II beta-chain paralogues and is present in a subgroup of
the human population. Antibodies against HLA-DRB3 are frequently encountered in organ
transplantation recipients. In case HLA-DRB3 would be taken along as unacceptable antigen
HLA-DRB301, 02, and 03 (and HLA-DRB103). The B cells were gated using a fluorescently labelled CD19 antibody
and the MFI values were corrected to MESF units using PE labelled beads. c. The relative mRNA expression of
HLA-DRB103, 11, 13, and 14 and HLA-DRB3 in isolated B cells from deceased donors (n = 5 per group)
determined by Q-PCR (normalized to HuPo). HLA-DRB101 was used as negative control for HLA-DRB1/3 primers.
A primer for HLA-DRB112 was not included, therefore the products are not amplified. d, e. The expression of
HLA-DRB3 on B cells with HLA-DRB103, 11, 12, 13, and 14 (n = 5 per group). HLA-DRB101 was used as
negative control. The cell surface expression is shown as MESF units. The HLA-DRB1 typing is shown in S1 Table.
Mann-Whitney t-test. The P values of<0.05 (),<0.01 (), and<0.001 () were significant.
https://doi.org/10.1371/journal.pone.0203381.g004
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during allocation, this will have a considerable impact on the donor frequency. Furthermore,
antibodies that are observed in patients that do not react with all tested HLA-DRB3 variants
in solid phase assays may have implications for HLA typing during allocation. We aimed to
examine the occurrence and reactivity of antibodies in organ transplant recipients. To this
end, we included a total of 85 transplant patients at two transplantation centres displaying
HLA-DRB3 antibodies. In a comprehensive screening of 645 patients with solid phase assays
we observed that 7% of patients develop antibodies throughout their time on the waiting list.
Fig 5. Graft survival in transplant recipients with or without HLA-DRB3 antibodies. a. Kaplan-Meier survival curve of transplanted grafts in
recipients with (n = 20) or without (n = 50) HLA-DRB3 antibodies. The loss of a transplanted graft (survival) was defined as the date of graft failure
after transplantation. Log-rank (Mantel-Cox) test with P<0.0001. b. The (v)PRA HLA class II percentage of the recipients with HLA-DRB3
antibodies. The (v)PRA was determined in the same serum sample as the HLA-DRB3 antibodies. (v)PRA = (virtual) panel reactive antibodies. c.
Overview panel indicating the moment when HLA-DRB3 antibodies were found in the 20 recipients with HLA-DRB3 antibodies. The light grey
squares show whether the antibodies were found before transplantation (pre tx), before graft failure (pre GF), after graft failure (post GF), or after
transplantectomy (post tect). Other detected donor specific antibodies are shown as a number or as not available (na) in the squares.
https://doi.org/10.1371/journal.pone.0203381.g005
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We observed that HLA-DRB3 antibodies develop upon different kinds of immunogenic events
including kidney transplantation, pregnancy, and transfusion. In 79% of patients with anti-
bodies against HLA-DRB3 did not carry the HLA-DRB3 gene, whereas 21% of patients that
also show these antibodies are carriers of the HLA-DRB3 gene. This indicates that not only
the presence of the HLA-DRB3 gene is immunogenic but also the allelic variation of the
HLA-DRB3 gene in different carriers.
In terms of antibody reactivity, we demonstrated in solid phase assays that multiple reac-
tivity patterns are observed, reflecting that HLA-DRB3 harbours multiple epitopes. The reac-
tivity patterns observed in patients that do not carry HLA-DRB3 are different from those
observed in HLA-DRB3 carriers. The pattern where all microbeads are recognized is the
most abundant pattern among all patients, and this is only observed in patients that do not
carry the HLA-DRB3 gene. In HLA-DRB3 carriers the HLA-DRB3 antibodies mainly reacted
with one or two microbeads. This is a clear indication that the epitopes, which are preferen-
tially recognized in HLA-DRB3 carrying patients are different from those patients that do
not carry the HLA-DRB3 gene. A limitation of these LSA assays is that there are only three
microbeads covering the major HLA-DRB3 alleles. This is insufficient to determine all epi-
topes that might be important for the immunogenicity of HLA-DRB3, and therefore specific
microbeads may be developed that cover more HLA-DRB3 alleles.
When we correlated the microbead reactivity pattern with the high resolution HLA-DRB3
typing of the immunizing events, we observed in almost all cases that the microbead carrying
the antigen of immunization was included in the reactivity pattern. However, we did observe a
vendor bias when comparing microbead-specific reactivity patterns with two different ven-
dors. This is primarily confined to individuals carrying the HLA-DRB3 gene. All microbeads
showed discrepancies in reactivity, but most were observed with the microbead containing
HLA-DRB303:01. The differences in reactivity can be a result of the purification and coating
of HLA-DRB3 proteins on the surface of microbeads or this reactivity can also be affected by a
different protein conformation of the coated HLA-DRB3 proteins [37]. Reed et al. performed
an extensive analysis of solid phase multiplex bead assays in the field of HLA antibodies, in
which they showed that the MFI was various according to the vendor and microbead type
[38]. Currently, it remains unclear what the clinical relevance of these allele-specific antibodies
is, nevertheless our results indicate that these antibodies develop as a result of immunization
and that they are not artefacts in solid phase detection systems.
When assessing the graft outcome in kidney transplant recipients who develop HLA-DRB3
antibodies, we observed that these patients demonstrate an inferior graft outcome as compared
with a control group that did not develop these HLA-DRB3 antibodies. It should be noted that
this is not considered proof of the clinical relevance of these antibodies, since in the majority
of patients (15 out of 20) these antibodies developed after graft failure or transplantectomy
and are therefore not involved in graft loss. Because these HLA-DRB3 antibodies arise at the
same time when a wide antibody response against a variety of HLA molecules, may indicate
that HLA-DRB3 antibodies are induced preferentially when a robust antibody response is
observed. A short graft survival followed by rapid transplantectomy is apparently associated
with the occurrence of these antibodies. Notably, the HLA-DRB3 antibodies that are induced
as a result of other immunizing events are not invariably associated with a diverse antibody
response (data not shown). In addition, the inferior graft outcome in these recipients can be
partly attributable to the donor origin, since all these patients received post-mortem grafts
from either DBD or DCD donors. The quality of post-mortem grafts is associated with
inferior transplant outcome as compared to living graft donors [39]. Although these data pro-
vide an indication about the role of HLA-DRB3 antibodies in kidney transplantation, this
study was not intended to assess graft outcome as it shows limitations such as the number of
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included patients and that our population is homogeneously Caucasian. With respect to the
clinical relevance, an additional analysis was performed by the Dutch PROCARE consortium
[40]. Only 50 transplantations (out of 577) were HLA-DRB3 mismatched as compared to 85
without HLA-DRB3 mismatch. This analysis showed that an HLA-DRB3 mismatch was not
associated with an inferior graft outcome (data not shown). Importantly, increasing the num-
ber of patients in an international multicenter study is essential to gain more insight in the
overall prevalence of HLA-DRB3 antibodies and the clinical relevance of these antibodies in
transplantation.
Since the induction of an antibody response may be dependent on the dose of the antigen
on the kidney transplant, we questioned whether there are differences in the mRNA and pro-
tein expression of different donors depending on their HLA-DRB3 typing or based on their
HLA-DRB1 allele. We made use of a depository of HLA-typed frozen splenocytes from which
we isolated B cells to perform our expression studies. Importantly, the disadvantage of using
this material may be that the total process of harvesting splenocytes and isolating B cells may
influence the stability of the mRNA and proteins. Still, we observed comparable mRNA and
protein levels of HLA-DRB3 when we used fresh blood samples (data not shown). Further-
more, our findings are in line with previous studies that reported that the relative mRNA
expression of HLA-DRB1 is always higher than HLA-DRB3 [41, 42]. Emery et al. showed
that this difference in expression between HLA-DRB1 and HLA-DRB3 is caused by the pres-
ence of specific motifs (to which transcription factors bind) in the X box region of the promo-
tors of these genes [43]. Although HLA-DRB3 is always lower expressed than HLA-DRB1, we
observed consistent differences in the HLA-DRB3 expression across different HLA-DRB1
alleles. We did not address whether this expression difference is due to variances in the promo-
tor of HLA-DRB3 or whether regulatory motifs in cis outside the promotor region are involved.
Though, we observed an altered distribution of HLA-DRB1 alleles in the donors that lead to
the induction of HLA-DRB3 antibodies as compared to an HLA-DRB3+ population without
HLA-DRB3 antibodies. The reduced preponderance of HLA-DRB111 in the donors was in
line with a reduced cell surface expression of HLA-DRB3 in case of HLA-DRB111. Although
this expression study is limited in size, it provides support for the hypothesis that the capacity
to induce an antibody response to the HLA-DRB3 protein of a mismatched HLA molecule
may be dependent on the expression level of the molecule. These data add up to previous
reports that HLA expression levels contribute to transplant outcome. Petersdorf et al. reported
that the expression level of HLA-C and HLA-DP is of significant importance in influencing
the strength of alloimmune responses in recipients that had mismatched HLA loci [26, 28].
Furthermore, Zilinska et al. showed that HLA-G mRNA expression was increased in recipients
with acute rejection such as AMR and T cell-mediated rejection as compared to patients with
dysfunctional non-rejected grafts [44].
In addition to our observation that the expression level of a mismatched HLA-DRB3
molecule may be involved in antibody formation we also observed that not all HLA-DRB3
alleles are equally immunogenic. When comparing the distribution of the HLA-DRB3 alleles
in the immunizing events with a control population we observed a preponderance of the
HLA-DRB301 group of alleles. This may point towards an increased immunogenicity of
HLA-DRB301 as compared to HLA-DRB302 and HLA-DRB303. Furthermore, we observed
that also the exact HLA-DRB3 allele determines the capacity to induce an antibody response
and it is not plausible that a difference in expression is the cause of this discrepancy. Faner
et al. did not observe a difference in relative mRNA expression of HLA-DRB301 and 02 in
both B cells and monocytes [10]. Although we observed that the relative mRNA expression of
HLA-DRB301 in B cells was higher as compared to HLA-DRB302 and 03, this did not trans-
late into a difference in the cell surface expression of HLA-DRB3.
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In conclusion, our study showed that HLA-DRB3 antibodies are frequently detected in kid-
ney patients after different immunologic events including transplantation, pregnancy, and
transfusion. The induction of these antibodies after transplantation or transplant failure is
associated with a wide allosensitization. We demonstrated that HLA-DRB3 and its’ allelic
diversity is immunogenic, and that HLA-DRB3 harbours multiple epitopes. Importantly, we
provide a first indication that the risk of developing an antibody response against HLA-DRB3
is to a certain extent dependent on HLA expression. However, our study awaits confirmation
in an international multicenter study especially with regard to the clinical relevance of these
antibodies, which remain unclear. Furthermore, it should be investigated whether the
HLA-DRB301 group of alleles is more immunogenic than the other groups; and whether
lower expression of HLA-DRB3 in HLA-DRB111 haplotypes may underlie the underrepre-
sentation in the immunizing donors.
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